Glenmark, Merck reach truce in cholesterol drug patent dispute
Investors Put Off By 2016 Launch Date Given To Glenmark, Stock Sheds 1.7%
GLENMARK Pharmaceuticals and US drugmaker Merck & Co have settled out of court their patent dispute over cholesterol control drug ezetimibe but investors were unimpressed with the terms of the deal, sending the company
Publication Date:
12/05/2010